Clinical Considerations: New Anti-Inflammatories & New CFTR Modulators

New CFTR modulators for F508del mutations? New research into reducing inflammation in the CF lung?  In this issue, Dr. Jennifer Taylor-Cousar from National Jewish Health in Denver explains the potential clinical impact of new and emerging CF disease modifying therapies.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Leave a Reply

Your email address will not be published. Required fields are marked *